Anil Badhwar, MD
Allergy & Immunology · Searcy, ARNPI 1992764260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 30.7% of the total.
Across 125 payments — averaging $55.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Amgen$836
- Regeneron Healthcare Solutions, Inc.$349
- Paratek Pharmaceuticals, Inc.$301
- Blueprint Medicines Corporation$271
- plus $2K from 21 others
Across 38 payments — averaging $12,949 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$286K
- Novartis$97K
- Astrazeneca AB$73K
- Sanofi US Services Inc.$28K
- Chiesi USA, Inc.$6K
- Alk-abello, Inc$1K
What the payments were for
- Food & beverage$6,94999%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $2,148 |
| GSK | 37 | $1,065 |
| Amgen | 8 | $836 |
| Regeneron Healthcare Solutions, Inc. | 3 | $349 |
| Paratek Pharmaceuticals, Inc. | 3 | $301 |
| Blueprint Medicines Corporation | 6 | $271 |
| Phathom Pharmaceuticals, Inc. | 2 | $198 |
| Novartis | 6 | $193 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $169 |
| Abbott | 1 | $158 |
| Phadia US Inc. | 1 | $150 |
| UCB, Inc. | 1 | $147 |
| Sanofi | 3 | $145 |
| Genentech USA, Inc. | 3 | $140 |
| Gilead | 1 | $125 |
| Merck | 1 | $100 |
| Grifols USA, LLC | 2 | $95 |
| Boehringer Ingelheim | 2 | $95 |
| Pharming Healthcare, Inc. | 1 | $91 |
| Johnson & Johnson | 1 | $64 |
| Aimmune Therapeutics, Inc. | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| CSL Behring | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,987 in reported general payments places this provider in the 65th percentile of 26 allergy & immunology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $35,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $26,756 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $7,905 |
| DuleraMometasone/Formoterol | 21 | $7,104 |
| Azelastine Hcl | 200 | $4,525 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,270 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $2,218 |
| Ipratropium Bromide | 23 | $855 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $802 |
| Fluticasone Propionate | 55 | $784 |
| Ventolin HfaAlbuterol Sulfate | 11 | $599 |
| Famotidine | 44 | $373 |
| Topiramate | 16 | $128 |
| Montelukast Sodium | 23 | $122 |
| Doxycycline Hyclate | 13 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $2,148 | $40,08366 claims |
| GSKTrelegy Ellipta | $1,065 | $26,75636 claims |
| MerckDulera | $100 | $7,10421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 26 allergy & immunology providers in Arkansas.
Other allergy & immunology in Searcy
- Blake ScheerLittle Rock$81K
- Jim IngramLittle Rock$62K
- Karl SitzLittle Rock$19K
- Jenny CampbellRogers$13K
- Curtis HedbergRogers$11K
- Stacy GriffinLittle Rock$10K
- Adesua WejinyaRogers$10K
- Ashley StonerLittle Rock$7K
- Kim JacksonLittle Rock$6K
- Aubrey ZieglerFort Smith$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.